Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial ...

As we expected, no-moat Telix’s slightly updated product, Gozellix, has received US regulatory approval. Like Illuccix, which contributes practically all of Telix’s current revenue ...

We are pleased to be building upon our successful relationship to bring the accuracy and clinical utility of gallium-based imaging to even more patients across the country with Gozellix®.” ...

Telix Pharmaceuticals TLX recently announced a major step in expanding access to its next-generation prostate cancer imaging agent, Gozellix, by selecting Cardinal Health CAH as a key U.S ...

The pipeline includes promising candidates like Gozellix, Zircaix, and Pixclara, targeting prostate, kidney, and brain cancers, with potential multi-billion dollar market opportunities.

Gozellix is indicated for PET scan testing for men with positive prostate cancer lesions, and those who may have a recurrence of the disease. The Australian biopharmaceutical firm began U.S ...